Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Autologous hematopoietic stem cell transplantation

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44363   clinical trials with a EudraCT protocol, of which   7387   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    101 result(s) found for: Autologous hematopoietic stem cell transplantation. Displaying page 1 of 6.
    1  2  3  4  5  6  Next»
    EudraCT Number: 2011-002434-40 Sponsor Protocol Number: AST-MOMA Start Date*: 2012-03-23
    Sponsor Name:University Hospital Tuebingen
    Full Title: Highdose Chemotherapy and transplantation of 34+ selected stem cell for progressive systemic sclerosis Modification according to manifestation
    Medical condition: Systemic sclerosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10059040 Autologous peripheral haematopoietic stem cell transplant LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-003573-42 Sponsor Protocol Number: 232100-0131 Start Date*: 2014-11-11
    Sponsor Name:Västra Götalandsregionen
    Full Title: Antibody-mediated immune response after immunization with FSME-Immun(R) against Tick Borne Encephalitis(TBE) after hematopoietic autologous and allogeneic stem cell transplantation.
    Medical condition: Patients have undergone allogeneic or autologous stem cell transplantation for hematological malignancies.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-003026-26 Sponsor Protocol Number: ARL - GT 2005 Start Date*: 2008-09-15
    Sponsor Name:University Medical Center Hamburg-Eppendorf
    Full Title: High-dose chemotherapy with transplantation of gene-modified haematopoietic stem cells for HIV-positive patients with malignant diseases indicating an HSCT
    Medical condition: HIV-positive patients with any malignant disease of the haematopoietic system indicating haematopoietic stem cell transplantation (autologous or allogeneic)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10061624 AIDS related complication LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-013798-16 Sponsor Protocol Number: Start Date*: 2010-02-01
    Sponsor Name:Royal Liverpool and Broadgreen University Hospitals NHS Trust
    Full Title: A comparison of plerixafor/G-CSF with chemotherapy/G-CSF for stem cell transplantation
    Medical condition: Patients with lymphoma or myeloma, who require high dose chemotherapy with autologous stem cell rescue (known colloquially as an autograft). Plerixafor is used to mobilise the autologous stem cells...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10042613 - Surgical and medical procedures 10053946 Stem cell mobilization LLT
    14.0 10042613 - Surgical and medical procedures 10019028 Blood and blood product treatment HLT
    14.0 10042613 - Surgical and medical procedures 10042613 Surgical and medical procedures SOC
    14.0 10042613 - Surgical and medical procedures 10025309 Haematological and lymphoid tissue therapeutic procedures HLGT
    14.0 10042613 - Surgical and medical procedures 10053943 Haematopoietic stem cell mobilisation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-004122-41 Sponsor Protocol Number: 1 Start Date*: 2017-04-10
    Sponsor Name:Medical University Vienna, Dept. f. Transfusion Medicine
    Full Title: Plerixafor for stem cell mobilization in patients with multiple myeloma who mobilize moderate to optimize collection results - a randomized, placebo-controlled, double-blind study
    Medical condition: Stem cell mobilization with mozobil (plerixafor) in patients with multiple myeloma.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-003337-40 Sponsor Protocol Number: final version 2.0 Start Date*: 2006-02-13
    Sponsor Name:European Group for Blood and Marrow Transplantation (EMBT)
    Full Title: Autologous Stem Cell Transplantation for Crohn's Disease ('ASTIC'-Trial: Autologous Stem Cell Transplantation International Crohn's Disease Trial)
    Medical condition: Patients with Crohn's disease who have not responded to immunosupressant medication
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IT (Ongoing) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-001269-40 Sponsor Protocol Number: CT-1306 Start Date*: 2008-10-29
    Sponsor Name:Charité University Medicine
    Full Title: Induction of Tolerance with Immunoablation and Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Severe Systemic Lupus Erythematosus (SLE) Refractory to Standard Immunosuppressive Th...
    Medical condition: Patients with systemic lupus erythematosus (SLE) will be under investigation who show high disease activity despite treatment with standard immunosuppressive therapies: high-dose corticosteroids an...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: View results
    EudraCT Number: 2008-003537-25 Sponsor Protocol Number: 04032008 Start Date*: 2008-08-28
    Sponsor Name:University Medical Center Groningen
    Full Title: Can the steady-state hematopoiesis be improved post-ASCT by infusion of the autologous stem cell transplant directly in the bone marrow compartment.
    Medical condition: Study population - patient age 18-65 years - eligible for an ASCT for lymphoma or MM - at least ≥ 10 x 106 CD34+ cells/kg have been collected during the previous performed leucofereses procedure
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-001005-67 Sponsor Protocol Number: AlloRelapseMMStudy Start Date*: 2022-05-11
    Sponsor Name:University Medical Center Hamburg-Eppendorf
    Full Title: Allogeneic stem cell transplantation vs. conventional therapy as salvage therapy for relapsed / progressed patients with multiple myeloma after first-line therapy (AlloRelapseMMStudy)
    Medical condition: Multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2004-002944-90 Sponsor Protocol Number: EORTC 65041 Start Date*: 2005-07-26
    Sponsor Name:European Organisation for Research and Treatment of Cancer
    Full Title: A Multicenter, Open, Phase II Study to Estimate the activity and safety of Caspofungin (CASP) in the First-line Treatment of probable and proven Invasive Aspergillosis 'IA) in Patients with Hematol...
    Medical condition: Invasive aspergillosis in patients with haematological malignancies (HM)/autologous Hematopoietic Stem Cell Transplantation (HSCT) – group A- and patients with allogeneic HSCT transplantation – gro...
    Disease: Version SOC Term Classification Code Term Level
    7.1 10003488 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) BE (Completed) ES (Completed) IT (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2018-001715-79 Sponsor Protocol Number: BL-8040.SCM.301 Start Date*: 2019-05-14
    Sponsor Name:BioLineRx Ltd.
    Full Title: A Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Centre Study Evaluating the Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and G-CSF as compared to Placebo...
    Medical condition: Hematopoietic Stem Cell mobilization in Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Trial now transitioned) CZ (Prematurely Ended) ES (Ongoing) DE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-005210-20 Sponsor Protocol Number: 2005-005210-20 Start Date*: 2006-04-10
    Sponsor Name:CHU Sart-Tilman
    Full Title: Phase II trial of caspofungin as secondary prophylaxis for invasive fungal infections in patients with high-risk hematological malignancies undergoing intensive chemotherapy or hematopoietic stem ...
    Medical condition: Acute leukemia during induction or consolidation therapy. Autologous HSCT for a hematological malignancy. Standard allogeneic HSCT with a myeloablative conditioning regimen.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-000130-37 Sponsor Protocol Number: MM-SDX-105-01 Start Date*: 2014-09-12
    Sponsor Name:FONDAZIONE NEOPLASIE SANGUE ONLUS (FO.NE.SA. Onlus)
    Full Title: Prospective, phase II study to evaluate the efficacy and the safety of a combination of bendamustine-melphalan as preparative regimen to autologous transplantation of hematopoietic cells for multi...
    Medical condition: Multiple myeloma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-013856-61 Sponsor Protocol Number: ReLApsE_RV-MM-GMMG-340 Start Date*: 2010-07-14
    Sponsor Name:University Hospital Heidelberg
    Full Title: A phase III national, multicentre, randomized open-label study with Lenalidomide/Dexamethasone versus Lenalidomide/Dexamethasone and autologous stem cell transplantation followed by Lenalidomide m...
    Medical condition: Multiple Myeloma (1.-3. Progression/Relapse)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000054086 10067095 Multiple myeloma progression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-005046-10 Sponsor Protocol Number: HEMSC42 Start Date*: 2019-07-23
    Sponsor Name:Radboud university medical center
    Full Title: Anakinra: Efficacy of interleukin-1 pathway inhibitor anakinra for the management of fever during neutropenia and mucositis in patients with multiple myeloma receiving an autologous hematopoietic s...
    Medical condition: Febrile neutropenia and mucositis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004867 10028127 Mucositis LLT
    20.0 10005329 - Blood and lymphatic system disorders 10016288 Febrile neutropenia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000354-25 Sponsor Protocol Number: 2.1 Start Date*: 2021-11-11
    Sponsor Name:FINBA
    Full Title: A multicenter randomized trial of fosfomycin versus ciprofloxacin for febrile neutropenia in hematologic patients: efficacy and microbiologic safety.
    Medical condition: Post-chemotherapy neutropenia with high risk of developing infection in patients with acute leukemia undergoing induction, autologous or allogeneic hematopoietic stem cell transplantation.
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000835 Acute leukemia LLT
    20.0 100000004851 10076734 Chemotherapy induced neutropenia LLT
    22.0 100000004865 10067862 Allogeneic stem cell transplantation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-003657-87 Sponsor Protocol Number: BCNHL Start Date*: 2007-09-14
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: Reduced intensity conditioning with high-dose rituximab followed by allogeneic transplantation of hematopoietic cells for the treatment of relapsed/refractory B-cell non Hodgkin’s lymphomas
    Medical condition: B-cell non-Hodgkin lymphomas
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025320 Lymphomas non-Hodgkin's B-cell HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-001669-27 Sponsor Protocol Number: CLLX2 Start Date*: 2011-06-28
    Sponsor Name:Universitätsklinikum Heidelberg
    Full Title: A phase-III study on the value of allogeneic stem cell transplantation in poor-risk chronic lymphocytic leukemia by the German CLL Study Group (GCLLSG) and the German Cooperative Transplant Study G...
    Medical condition: High-risk and very high-risk chronic lymphocytic leukemia (CLL)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008962 Chronic lymphocytic leukaemia refractory PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-003572-23 Sponsor Protocol Number: GCP#01.01.030 Start Date*: 2017-12-27
    Sponsor Name:Gamida Cell Ltd
    Full Title: Allogeneic Stem Cell Transplantation of CordIn™, Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Patients with Hemoglobinopathies
    Medical condition: Hemoglobinopathies
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004850 10054658 Thalassemia LLT
    18.0 100000004850 10040645 Sickle cell disease NOS LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2004-001117-34 Sponsor Protocol Number: APL-B-013-02 Start Date*: 2004-10-13
    Sponsor Name:Pharma Mar S.A.
    Full Title: A Phase II Multicenter,Open-Label, Clinical And Pharmacokinetic Study Of Aplidin® As A 1-Hour Weekly IV Infusion, In Patients With Relapsed Or Refractory aggressive non-Hodgkin’s Lymphoma.
    Medical condition: Aggressive non-Hodgkin’s Lymphoma.For aggressive NHL patient cure is still the target of therapy and a CR is a prerequisite to achieve this goal. Salvage therapy needs more aggressive experimental ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Nov 04 03:15:13 CET 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA